Lumenis Be ANZ has launched OptiPlus in Australia and New Zealand, describing the device as “the first-ever dual frequency radiofrequency (RF) device designed specifically for eye care professionals”.

The new technology delivers therapeutic heat across multiple skin and tissue layers, boosting circulation to support both medical efficacy and aesthetic enhancement.¹

OptiPlus is designed to work synergistically with OptiLight – a light-based technology that targets the root cause of dry eye disease due to meibomian gland dysfunction (MGD).

DUAL-FREQUENCY TECHNOLOGY

In a media release, Lumenis said OptiPlus introduces “a novel RF approach that penetrates various skin depths, enabling targeted treatment of the meibomian glands while simultaneously stimulating collagen production and periorbital skin tightening”.1-3Lumenis said this dualaction uniquely positions OptiPlus to support both therapeutic outcomes and aesthetic goals – a combination increasingly sought after by modern practices.

A standout feature of the device is its proprietary monopolar electrode, which is ergonomically designed to follow the delicate contours of the periorbital area. According to Lumenis, this ensures precision, comfort, and safety – with pre-programmed, clinically validated settings and integrated temperature control technology supporting consistent and optimal results across all skin types.4

POSITIVE REAL-WORLD RESULTS

Dr James Chelnis, an ophthalmologist at Manhattan Face and Eye in the United States, said he was “thrilled” to incorporate OptiPlus into his clinic’s treatment regimen.

As the lead investigator in a recent clinical study, he reported seeing “outstanding results using OptiLight to manage dry eye disease”.

“In our study, we recorded a 150%+ increase in expressible meibomian glands, a 70% improvement in meibum quality, and over a 60% reduction in dry eye symptoms.³ Plus, the aesthetic benefits of RF skin rejuvenation are a welcome bonus for many patients.”

FUTURE-READY CLINICS

Tracey Cannon, Director of Marketing and Clinical Affairs, Lumenis ANZ, said the “first-ofits-kind technology” would become “a catalyst for transformation in both clinical practice and patient experience”.

“With OptiLight and OptiPlus working hand in hand, eye care professionals now have an extraordinary opportunity to build thriving, future-ready practices,” she concluded.

References available at mivision.com.au.